Indo Borax launches ₹150 crore open offer for Kronox Lab Sciences
- Indo Borax launches mandatory open offer for 25.79% stake in Kronox Lab Sciences
- Offer price set at ₹157.27 per share, totaling maximum consideration of ₹150.5 crore
- Acquirer secures 64.26% stake via separate share purchase agreement with promoters
- Total financial arrangement includes ₹134.0 crore cash reserves and ₹25.0 crore PAC support

*this image is generated using AI for illustrative purposes only.
Indo Borax and Chemicals Limited has initiated a mandatory open offer to acquire a controlling stake in Kronox Lab Sciences . The acquirer aims to purchase up to 95,70,000 equity shares, representing 25.79% of the target’s voting share capital, at an offer price of ₹157.27 per share.
The transaction follows the execution of a share purchase agreement dated August 20, 2026, wherein Indo Borax agreed to acquire 64.26% of Kronox Lab Sciences from its existing promoters. Zenrock Chemicals Private Limited acts as a person acting in concert (PAC) with the acquirer. The total maximum consideration for the open offer stands at ₹150.5 crore, assuming full acceptance by public shareholders.
Offer Price and Valuation
The offer price of ₹157.27 per equity share was determined in accordance with SEBI (SAST) Regulations. It reflects the volume-weighted average market price of the shares on the National Stock Exchange over the 60 trading days preceding the public announcement. This price significantly exceeds the negotiated share purchase agreement price of ₹103.22 per share (₹105.87 inclusive of consultancy fees) paid to the selling promoters.
Financial Arrangements
Indo Borax has confirmed firm financial arrangements to meet the obligations under the open offer. The acquirer holds cash and cash equivalents of ₹134.0 crore as of August 19, 2026. Additionally, the PAC, Zenrock Chemicals, has committed ₹25.0 crore in financial support. A total escrow amount of ₹38.0 crore, representing 25.25% of the maximum consideration, has been deposited with Kotak Mahindra Bank Limited.
Target Company Profile
Kronox Lab Sciences manufactures high-purity specialty fine chemicals for pharmaceutical, nutraceutical, and biotech sectors. The company reported total income of ₹1,064.1 crore and profit after tax of ₹276.6 crore for FY26. For the quarter ended June 30, 2026, revenue stood at ₹296.8 crore with a net profit of ₹73.0 crore.
What the Numbers Show
The disparity between the negotiated promoter exit price and the public offer price highlights a significant value transfer to minority shareholders. While the promoters sold their stake at an effective price of ₹105.87 per share, public shareholders are being offered ₹157.27 per share. This premium of approximately 49% over the negotiated price underscores the regulatory requirement to protect minority interests in substantial acquisitions, potentially leading to immediate arbitrage opportunities if the market price remains below the offer price during the tendering period.
Historical Stock Returns for Kronox Lab Sciences
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -4.61% | -3.54% | +15.45% | +49.87% | +6.95% | 0.0% |
How might the integration of Kronox Lab Sciences' specialty chemical portfolio affect Indo Borax's long-term revenue diversification and margin profile?
What impact will the ₹150.5 crore cash outflow and escrow deposits have on Indo Borax's liquidity position and future capital allocation strategies?
Could the significant premium offered to public shareholders trigger a broader wave of mandatory open offers in the Indian specialty chemicals sector?


































